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Summary Lymphocytes from 180 patients with a variety of malignant diseases were collected and fused with
a human myeloma-derived line, LON-LICR-HMy2/CAMl. A total of 162 hybridomas was obtained. Only B
lymphocyte markers were found on the surface of the fusion products. Flow cytometric analysis revealed a
stably increased DNA content in the hybridoma cells. Some hybridoma supernatants were found to contain
new Ig chains. Anti-tumour binding activity was found in 12 supernatants.
Monoclonal antibodies (McAbs) allow the precise
definition of individual components of complex
antigenic structures, such as tumour cell surfaces.
Mouse and rat monoclonal antibodies raised
against human tumour cells have identified
molecules that are present in greater quantity on
tumours when compared with normal cells (Lennox
& Sikora, 1982; Marx, 1982). Such antibodies have
already been shown to have clinical use in diagnosis
by providing markers of tumour load (Koprowski
et al., 1981), and for radiolocalisation of tumour
deposits (Mach et al., 1982). Promising preliminary
results in therapeutic trials with these antibodies in
patients with colorectal cancer (Sears et al., 1982)
and nodular lymphoma (Miller et al., 1982) have
recently been reported. A major problem with such
antibodies has been their lack of specificity.
Although the target antigens recognised may often
be expressed in increased quantities on tumour
cells, most McAbs show no absolute tumour
specificity (Brown et al., 1981; Lennox & Sikora,
1982). Many of the antigens are present in small
quantities on stem cells in normal tissue. The
xenogeneic immunisation schedules used in the
preparation of these McAbs emphasise certain
components on the cell surface such as the blood
group substances and histocompatibility antigens
which are shared by normal and neoplastic cells. A
further problem with xenogeneic McAbs is the
immune response to them when used clinically,
which may abrogate their effects. Furthermore, no
information may be derived about the way in which
the host's immune system is responding to the
presence of autologous tumour.
There is considerable evidence that patients are
able to mount a serological response to their own
neoplastic cells, at least at some stages of the
natural history of their disease (Shiku et al., 1977).
By fusing lymphocytes likely to be involved in this
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response with a suitable myeloma line, hybridomas
can be produced and antibody activity analysed.
There have been several reports of hybrid cell lines
generated by fusion of human lymphocytes to
mouse and rat myelomas (Table I). Indeed a McAb
against a measles virus antigen has been produced
in this way using lymphocytes from a patient
infected with the virus (Croce et al., 1980). Such
inter-species hybrids shed human chromosomes
preferentially, so rapidly losing the ability to
immortalise human immunoglobulin genes from the
donor lymphocytes. Although early and repetitive
cloning of the hybrids can reduce the shedding of
human chromosomes (Wunderlich et al., 1981), it is
clear that the development of a stable human
hybridoma system using a suitable human myeloma
would be of advantage. Several human systems
have now been described in the literature (Table II).
We have chosen to use the LICR-LON HMy2
line in our attempts to make human McAbs to a
wide range of tumour types using lymphocytes from
several sources. Peripheral blood, regional lymph
node, and intra-tumoural lymphocytes have been
collected and fused. After cloning, the supernatants
were screened for anti-tumour activity on cell lines.
This paper reports our attempts to make human
anti-tumour monoclonal antibodies from material
from 180 patients.
Materials and methods
Tumour and lymphocyte collection
We collected tumour material and, where available,
regional lymph nodes from patients undergoing
surgery for a variety of cancers. One gram of
tumour was cut into 1 mm cubes using fine scissors
in Earle's balance salt solution and frozen in liquid
nitrogen. Pieces of corresponding normal tissue,
where available, were similarly stored. Lymphocytes
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Table I Inter-species hybrids using human lymphocytes
Fusion cell Human Ig Sources of
Author line (ugml 1) human lymphocytes Activity
Schwaber & Cohen
(1974) TEPC-19 - Peripheral blood
Levy et al.
(1978) NS1 - CLL/NLPD
Schlom et al.
(1980) NS1 0.1-20 Lymph node anti-breast carcinoma
Nowinski et al.
(1980) NS1 Spleen anti-Forssman antigen
Croce et al.
(1980) NS1 5-10 Peripheral blood anti-measles virus
Sikora & Wright
(1981) NS1/Y3 0.1-10 Lymph node anti-lung carcinoma
Table II Human hybridoma systems
Author/Fusion cell type Derivation Selection Ig Antibody ugml1
Croce et al., (1980)
GM-1500-6TGA1 GM1500 6TG K y anti measles
Edwards et al., (1982)
LICR-LON-HMy2 ARH77 6TG K Y 0.1-1
Kaplan & Olsson
U266 ARI (1980) U266 8AG e y anti DNCB 3-10
Clark et al., (1981) RPM1 0
RPM1 8226 8226
6TG =6 thioguanine; 8AG=8 azaguanine.
were purified from peripheral blood using standard
Ficoll-Paque techniques (Hutchins & Steel, 1979).
Lymph nodes were teased apart by forceps and
dead cells removed by Ficoll-Paque sedimentation.
Intra-tumoural lymphocytes were collected from
patients with poorly differentiated gliomas in a
similar manner. Overall yields varied from 1-
30 x 107 viable lymphocytes.
Cellfusion
Cell fusion was carried out using polyethylene
glycol (PEG) following the general procedure
outlined by Hales (1977). An 8-azaguanine (8AG)
resistant human lymphoid cell line, LICR-LON-
HMy2 (Edwards et al., 1982), was used which was
sensitive to hypoxanthine, aminopterin and
thymidine (HAT) medium. This line was adapted
for growth on serum-free medium and cloned.
Several clones were tested for fusion with peripheral
blood lymphocytes and one LICR-LON-
HMy2/CAMI (subsequently referred to as HMy2)
chosen for further study. For each fusion, the
recovered lymphocytes and a constant number of
5 x 107 myeloma cells were suspended in serum-free
Dulbecco's modified eagles medium (DMEM),
mixed, and centrifuged at 1500rpm for 10min in a
50ml conical-bottomed plastic centrifuge tube. The
supernatant was drained off completely. Five
hundred microlitres of PEG M.W. 1000, 41.7%
(w/v), with 15% dimethyl sulphoxide (DMSO) in
serum-free DMEM was added to the pellet, and theHUMAN HYBRIDOMAS FROM CANCER PATIENTS 137
cells gently resuspended using the tip of the pipette.
After 1 min, 0.5ml of PEG 1000, 33% (w/v) in
serum-free DMEM, but without DMSO, was
added, and the mixture stirred gently for 3min.
Four millilitres of DMEM with 10% foetal calf
serum (FCS) was added dropwise, and the mixture
rocked for a further 4min. Forty-five ml of DMEM
with 10% FCS was slowly added, and the mixture
was taken up carefully in a wide bore 25ml pipette,
and dispensed equally into each of 96 (2ml) wells of
4 Linbro plates. One ml of DMEM with 10% FCS
was added to each well, and renewed after 2h. After
24h, the medium was partly replaced by selected
medium containing HAT 20% FCS (Miller &
Ruddle, 1976). The selective medium was renewed
daily for at least the first 2 weeks. Hybrid clones
visibly appeared in some wells between 3-6 weeks
after fusion. Supernatants from well-grown wells
were taken for testing, supplemented with 10mM
Hepes buffer and 0.1% sodium azide, and stored at
4°C. Bulk supernatants from cloned hybrids
growing in roller bottles were in Iscove's (Flow
Laboratories) (Iscove & Melchers, 1978) serum-free
medium supplemented with 5pgml-1 of insulin.
Bulk supernatants were harvested and concentrated
using Millipore CX-10 (10,000 daltons exclusion)
ultrafiltration unit.
Immunoglobulin (Ig) assay
Rabbit anti-human Ig antisera (Miles Laboratories)
was diluted in phosphate buffered saline (PBS) to
1/1000. Fifty A aliquots were added to round-
bottomed 96-well vinyl plastic plates and incubated
overnight at 4°C. These plates were subsequently
washed in medium containing Earle's buffered salt
solution, 1% bovine serum albumin, 0.01% sodium
-azide, adjusted to pH 7.4 by 1 M sodium hydroxide.
After washing 4 x by decanting the contents of the
wells and replacing with a 5Oyl of medium, the
plates were left for 1 h at room temperature and
again washed as previously described. Fifty pl of
chain-specific monoclonal mouse anti-human Ig was
added (Bethesda Research Laboratories) at a
concentration of 1/5000. After 1 h incubation with
the relevant monoclonal antibodies, the plates were
washed and rat anti-mouse Ig coupled to I125 using
the chloramine-T method was added. After a final
incubation of 1 h and 4 subsequent washes in
complete medium, the plates were air dried, the
wells cut with a hot wire, and counted in a y
counter.
Surface typing ofhybridomas
This was carried out by indirect
immunofluorescence (Dorreen et al., 1982). Cells
were washed in acetate buffer (pH 5.5) to remove
non-specifically adsorbed Ig and incubated in
medium for 2h. One million washed cells were
incubated with monoclonal antibody against
different lymphocyte subset antigens. These
antibodies included the anti-Ig chain-specific
McAbs (Bethesda Research Laboratories); anti-
human p-2 microglobulin (clone 26/114 HLK, Sera
Lab); anti-HLA (W6-32); anti-Ia (New England
Nuclear, NE1/011); anti-Lyt3 reacting to T-
lymphocytes (Becton Dickinson); OKT4 anti-
inducer/helper T-lymphocytes (Ortho-
Pharmaceuticals) OKT6, anticortical thymocytes
(Ortho-Pharmaceuticals) and OKT8, anti-
suppressor/cytotoxic T-lymphocytes (Ortho-
Pharmaceuticals). After 1 h at 4°C the cells were
washed in medium and then incubated with
fluorescein isothiocyanate (FITC)-conjugated rabbit
anti-mouse Ig (1:64, Miles). After a further 1h at
4°C the cells were washed, suspended in 1% glycerol
and examined. Surface Ig expression was quantified
by flow cytometry. Cells were incubated for 1 h at
4°C with FITC-conjugated rabbit anti-human Ig,
washed in EBSS containing 1% BSA, and examined
on a flow cytometer.
DNA content
Hybridomas were cultured in 25ml-tissue culture
flasks in log phase. Cells were washed twice in
EBSS containing 1% BSA and adjusted to 106
cellsml-'. Cells were pelleted and resuspended in
ethidium bromide (0.05mgml-1) in hypotonic (0.1%)
sodium citrate. DNA histograms were obtained by
means of a custom-built flow cytometer which
incorporated an argon laser (Watson, 1981).
Electron microscopy
Five million cells were fixed in 3% glutaraldehyde
in 0.1 M HEPES for 20min. After washing in 0.1 M
HEPES, cells were suspended in 1% osmium
tetroxide in 0.1 M HEPES for 20min, rewashed and
suspended in 1% uranyl acetate for 30min. After
dehydration the cells were mounted in araldite
blocks and examined by electron microscopy.
Anti-tumour antibody activity
Avarietyofhumantumourcelllineswereusedtoassess
binding activity in an indirect radioimmunoassay.
These included G/CCM glioma (gift of 1. Freshney)
HT29 colorectal carcinoma (from J. Fogh); MOR
lung adenocarcinoma (M. Ellison); Calu-1
squamous cell lung carcinoma (J. Fogh); MCF-7 (P.
Rudland); and the MRC5 fibroblast line. Freshly
trypsinisedcellswerewashed3 x bycentrifugationand138 K. SIKORA et al.
suspended in assay medium identical with that used
for Ig typing. Viable cells were counted by trypan-
blue exclusion and adjusted to a concentration of
2 x 106 ml-'. Fifty ,ul of cell suspension was placed
into each well of round-bottomed Cooke microtitre
plates which had been previously incubated
overnight with 504l well of poly L-lysine in
phosphate buffered saline at 37°C. The cells were
fixed for 1 h in 0.25% glutaraldehyde and washed
3 x in medium. Fifty ,l of supernatant was added
and incubated at room temperature for 1 h. After
washing three times 50pl of mouse anti-human light
chain antibody at a dilution of 1/5000 was added
and incubated for 1 h. The final stage of the assay
was the addition of 50pl radioiodinated rabbit anti-
mouse Ig. After a further hour the cells were
washed and counted on a y counter.
Results
Cellfusion
Clinical material was obtained from 180 patients
with a variety of tumours over the course of 1 year
(Table III). Apparently successful initial fusion was
observed in 55 patients. Low lymphocyte yields and
infection were the major problems in the early
stages. Infection was a particular hazard in samples
from patients with colorectal carcinoma where
lymph nodes and contaminated large bowel were
placed in a single sterile container for delivery to
the laboratory. Cloned hybrids were obtained in 24
patients. Hybrids appeared between 4-8 weeks
following fusion and were seen as clumps of piled-
up cells amongst the debris of dying normal
lymphocytes and HMy2 cells (Figure 1). Once
established, hybridomas were rapidly growing with
doubling times of 24-36h. All hybrids tested were
easily adapted for growth in serum-free (Iscoves)
medium in 41 roller bottles.
Ig secretion
All hybridomas continued to produce the K and y
chains secreted by HMy2. In addition, 14%
produced A chains, 15% p chains, 13% a chains and
1% e chains (Table 4). The production of new Igs
continued after prolonged tissue culture. One-
5,ugIgml-' was detected in the supernatants.
Lymphocyte antigens and human hybridomas
Table V outlines the results of indirect
immunofluorescence using a set of commercially
available McAbs to lymphocyte differentiation
antigens. Peripheral blood lymphocytes from a
normal donor showed partial reactivity to all typing
reagents. HMy2 contained surface K and y Ig, as
Table Ill Human hybridoma production
Samples Lymphocyte Successful Patients with Total
Tumour produced origin fusion hybrids hybrids
Lung 14 RN 8 2 27
Breast 29 RN 13 4 28
Colorectal 42 RN 12 3 6
Glioma 39 IT 18 9 84
Kidney 3 RN 0 0 0
Sarcoma 2 IT 0 0 0
Melanoma 2 RN 1 1 1
Uterus 13 RN 5 2 7
Stomach 14 RN 5 1 7
Bladder 18 RN 0 0 0
Burkitts 4 PB 3 2 2
RN regional node.
IT intratumoural
PB peripheral bloodHUMAN HYBRIDOMAS FROM CANCER PATIENTS 139
Table IV Human immunoglobulins produced by
hybridomas
Table V Lymphocyte antigens on
human hybridomas
PBL HMy2 Hybridomas
Ig secreted
Total
Tmour hybrids K A y v I a e
Lung 27 27 4 27 6 1 1
Breast 28 28 3 28 5 4 0
Colorectal 6 6 1 6 1 0 0
Glioma 84 84 13 84 11 15 2
Melanoma 1 1 0 1 0 0 0
Uterus 7 7 2 7 1 0 0
Stomach 7 7 0 7 0 1 0
Burkitts 2 2 0 2 0 0 0
aIgK + +
aIgA +
algy + +
alIg +
aIga ± +
aOi2m + +
aHLA + +
ala + +
aLyt3 +
OKT4 + -
OKT6 + -
OKT8 +
Figure 1 Human hybridoma cells growing in HAT. Debris of dying lymphocytes and HMy2 cells in
background.
+
+
+
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well as /3-2 microglobulin, HLA and IA. No T-cell
markers were noted. A set of 20 hybridomas were
typed. Surface Ig expression corresponded with
detected chains secreted into the supernatant. All
hybridomas expressed P-2 microglobulin, HLA and
IA. No T-cell antigens were expressed in any of the
hybridomas tested. Figure 2 shows the flow
cytometry analysis of surface Ig content detected by
polyclonal rabbit anti-human Ig. Peripheral blood
lymphocytes show a slight increase over the HMy2
content of surface Ig. All hybrids tested show a
considerable increase in the amount of Ig expressed.
DNA content
Figure 3 shows the DNA content of lymphocytes,
HMy2 and one hybridoma. The DNA content of
the hybrid cell is approximately the sum of that of
the parent myeloma, plus that of the lymphocytes.
After 8 months of continuous culture, no change
was observed in this increased DNA content.
Electron microscopy
Figure 4 shows electron microscopy of HMy2 and a
resultant hybridoma, LGLL-lD6. The endoplasmic
reticulum was poorly developed.
Anti-tumour antibody activity and specificity
Antibodies were initially screened for binding
activity against the cell line most appropriate to the
HMy 2 source of donor lymphocyte. An initial screen of 40
hybridoma supernatants is shown in Figure 5.
Despite the sensitivity of the binding assay, the
counts bound were low. After concentration,
however, (Figure 6), titration curves were obtained.
These curves show only weak binding of antibody.
However the binding was significantly above
LYMPH background when compared to that of HMy2 Ig at
similar concentration (Figure 6). The specificity of
binding was determined using several tumour cell
lines (Table VI). Peripheral blood lymphocytes and
red blood cells from normal donors were used as
controls. It can be seen that all the antibodies
isolated so far bind to a variety of cell types and
LGLI-lD6 ~ are not individually tumour-specific. More precise
definition of specificity was attempted using
immunohistological methods on fresh frozen
biopsies of tumour and normal tissue. No
significant binding above background was observed
despite clear immunofluorescence p4tterns with cell
lines.
LC04 -4 D6 Discussion
LBR6-2C6
Surface Ig
Figure 2 Surface Ig expressed on lymphocytes, HMy2
cells and 3 hybridomas detected using FITC-anti
human Ig and flow cytometry.
In this paper we have demonstrated that
lymphocytes from patients with several tumour
types can be successfully fused with a human
myeloma line to produce stable hybridomas. These
hybridomas secrete Igs, several of which have been
found to show weak binding to tumour cell lines in
an indirect radioimmunoassay. Evidence for
hybridisation, rather than outgrowth of
lymphoblastoid lines from the patients lymphocytes,
is provided by the continued secretion of HMy2 Ig
as well as the new lymphocyte Ig in cloned
hybridomas. Flow cytometric DNA analysis shows
the stably increased DNA content characteristic of
hybrids. Formal karyotypic analysis has been
performed on hybridomas derived from HMy2HUMAN HYBRIDOMAS FROM CANCER PATIENTS 141
LYMPH
HMy 2
LGLI-1D6
DNA content
Figure 3 DNA content of lymphocytes, HMy cells
and LGL1-ID6 hybridoma.
which confirm a stably increased chromosome
number (Edwards et al., 1982).
There are several problems with the LICE-
LON-HMy2 hybridoma system. Firstly, the low
fusion frequency results in a large workload to
produce small numbers of hybrids. Several methods
have been used in attempts to increase this
frequency. These have included provision of feeder
cells and secondary in vitro stimulation by either
antigen (tumour cells) or by pokeweed mitogen. No
increase in fusion frequency was observed. A second
problem is the continued secretion of the HMy2 c
and y immunoglobulin chains by the hybridomas. A
true assessment of the numbers of hybrids secreting
Ig coded for by genes of the donor lymphocytes is
thus difficult. Furthermore, mixed antibody
molecules comprised of chains coded by both
myeloma or lymphocyte genes will occur. Such
molecules will have reduced antibody activity. A
third problem is the low antibody secretion rate of
between I and 51tgml-'. Large amounts of tissue
culture supernatant must be concentrated in order
to increase signal-to-noise ratio in the
radioimmunoassay. The poorly developed
endoplasmic reticulum in all hybrids examined by
electron microscopy suggests that the rate of
protein synthesis may well be limiting. The initial
screen for anti-tumour antibody activity may be
unable to detect the small amounts of weak
antibodies. Finally, the low anti-tumour binding
activity hinders the analysis of specificity of the
resulting antibodies. A combination of low secretion142 K. SIKORA et al.
HMy 2
Figure 4 Electron microscopy of HMy2 and LGLl-1D6 ( x4000).
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Figure 5 Initial screening assay for anti-tumour binding activity. Forty supernatants tested on GCCM-a
rapidly-growing human glioma line.
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Figure 6 Concentrated supernatants (x40) titrated in binding assay against GCCM. 0 O LGLI-lD6;
A/ A LGL1O-3B5; * * HMy2 sup.
rate, mixed Ig chain molecules, and low affinity may
all contribute to this low binding. Our attempts to
produce a high secreting variant of HMy2 by
dilution cloning and subsequent assay have so far
been unsuccessful.
The specificity studies on 12 antibodies clearly
show a wide range of weak binding to different
tumour cell lines. It is of interest that none of the
antibodies bound to the benign fibroblast line
(MRC5), normal red cells, or peripheral blood
lymphocytes. Our attempts to localise the antigens
by immunohistological techniques have so far been
unsuccessful due to a combination of weak binding
and high background Ig in human tissues. We are
currently using immunochemical methods to detect
G
the presence of the recognised antigens on a variety
of human tissue types. Despite the apparent lack of
specificity to individual tumours, human
monoclonal antibodies may well have significant
diagnostic and therapeutic implications in clinical
oncology.
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Table VI Binding of human hybridoma supernatants to various human cell lines,
peripheral lymphocytes and red cells
Supernatant G/CCM HT29 MOR CALU 1 MCF7 MRC5 PBL RBC
Glioma
LGL-11C3 +++ ++ + - + - - -
LGL1-1C6 +++ ++ + - ++ - - -
LGL1-1D6 ++ + ++ + + - + -
LGL1-2C1 ++ ++ + + - _ - +
LGL7-1A2 ++ + + - + + - +
LGL7-3A2 ++ + + ++ _ _ _ _
LGL1O-3B5 ++ + + - ++ - _ _
LGL22-4D6 ++ + ++ + + - - +
Lung
LLU1-3D1 ++ ++ ++ ++ + - _ +
LLU6-lA1 ++ + ++ ++ + + - +
LLU6-2A4 ++ + + + _ _ _ _
LLU6-3D4 ++ + ++ ++ + - _ -
- 0-50c.p.m.
+ 50-100
± 10150 a10ve HMy2 supe5natant background
+ + 150-200
+++ >200
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